Chroman Derivatives for COPD Inhalation Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic obstructive airway diseases such as COPD, asthma, and bronchiectasis often require multiple medications and have limitations in providing both bronchodilating and anti-inflammatory effects without causing desensitization, and existing drugs are not effective in addressing chronic inflammation and airway obstruction effectively.
Innovation Solution
Development of compounds with a chroman skeleton, specifically formula (I), (II), and (III), which are derived from trolox and have bronchodilating and anti-inflammatory properties, suitable for inhalation, and can be administered through a nebulizer to target chronic obstructive airway diseases, maintaining activity over long-term use without desensitization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If multiple medications are used to treat chronic obstructive airway diseases, then the therapeutic coverage is improved, but the treatment complexity increases
Solution Approach 1:
The patent combines bronchodilating and anti-inflammatory effects into a single chroman derivative compound, eliminating the need for multiple medications while maintaining comprehensive therapeutic coverage for chronic obstructive airway diseases
2Reliability
If existing drugs are used to address chronic inflammation and airway obstruction, then some symptomatic relief is achieved, but desensitization occurs over time
Solution Approach 1:
The patent modifies the chemical structure by introducing specific substituents at the 6-position of the chroman ring, creating derivatives with optimized pharmacological properties that maintain effectiveness over long-term use without causing desensitization
3Reliability
If inhaled medications are administered to target lung diseases, then localized treatment efficacy is improved, but absorption efficiency must be optimized
Solution Approach 1:
The patent optimizes the lipophilicity and molecular weight of chroman derivatives to enhance their absorption through inhalation, ensuring efficient delivery to lung tissue while maintaining appropriate pharmacokinetic properties for localized action
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to compounds for the treatment of chronic obstructive airway diseases such as chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis. The present invention further relates to drug delivery devices suitable to be used in the treatment of chronic obstructive airway diseases such as a nebulizer comprising the present compounds. Specifically, the present invention relates to (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-1-yl)methanone or N,6-dihydroxy-2,5,7,8-tetramethylchroman-2-carboxamide or a pharmaceutically acceptable salt or base thereof for use in the treatment of chronic obstructive airway diseases, preferably chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis, more preferably chronic obstructive pulmonary disease (COPD).